Glenmark Pharmaceuticals surges on initiating multi-country Phase 3 Clinical Trial for Envafolimab
The company has received approval from the Drugs Controller General of India (DCGI) to begin patient enrolment and dosing in the country
Glenmark Pharmaceuticals is currently trading at Rs. 2045.75, up by 55.15 points or 2.77% from its previous closing of Rs. 1990.60 on the BSE.
The scrip opened at Rs. 1990.60 and has touched a high and low of Rs. 2055.15 and Rs. 1990.60 respectively. So far 15447 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2286.15 on 11-Jul-2025 and a 52 week low of Rs. 1274.70 on 28-Feb-2025.
Last one week high and low of the scrip stood at Rs. 2055.15 and Rs. 1903.50 respectively. The current market cap of the company is Rs. 57879.39 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 38.30% and 15.06% respectively.
Glenmark Pharmaceuticals has initiated a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting. The company has received approval from the Drugs Controller General of India (DCGI) to begin patient enrolment and dosing in the country.
In parallel, the company has submitted a Clinical Trial Application (CTA) in Russia and is preparing to open additional clinical trial sites in Brazil and Mexico, further expanding the global footprint of this pivotal study. The randomized, multi-center, Phase 3 trial will assess the efficacy, safety, pharmacokinetics, and immunogenicity of Envafolimab in patients with resectable Stage IIIA and IIIB (N2) NSCLC, while a parallel Phase 3 study of Envafolimab sponsored by 3D Medicines Inc., was initiated in December 2023 and is actively recruiting in China.
Lung cancer remains the leading cause of cancer-related deaths worldwide, with NSCLC comprising approximately 80-85% of cases, and 20-30% diagnosed at Stage III. Despite surgical options for a subset of Stage III patients, five-year survival remains poor, ranging from 36% and 26% at Stage IIIA and IIIB respectively. These outcomes highlight the urgent need for innovative, accessible immunotherapy options like Envafolimab to improve prognosis in resectable Stage III NSCLC.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
